In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
ICON eyes growing virtual clinical trial market with $12 bln PRA Health deal
An article reporting on ICON's acquisition of contract research organisation PRA Health Sciences.
-
COVID trials vaccine firm ICON announces €10bn US takeover deal
ICON has announced one of the biggest takeover deals in Irish corporate history.
-
ICON to buy contract researcher PRA Health for $12B
ICON will buy PRA Health Sciences for about $12 billion in cash and stock, snapping up one of the larger independent companies in the drugmaker services business.
-
ICON plc acquires PRA Health Sciences Inc. in $12 billion acquisition
In a cash and stock transaction value of approximately $12 billion, ICON plc has announced its acquisition of PRA Health Sciences as part of a focus on innovative and high-quality clinical trials.
-
CRO consolidation continues with ICON buying PRA Health Sciences for $12B
ICON is set to acquire rival PRA Health Sciences in a $12 billion deal that will vault the combined company into second place among clinical trial services providers.
-
How to manage the impact of COVID-19 on IVDR timelines
Angela Brown and Nicole A. Cowan, Director examine how IVD manufacturers can meet 2022 deadlines despite the COVID-19 pandemic.
-
Decentralised, hybrid or traditional: Choosing the best option for your clinical trial
In this article, EB McLindon offers insights to help sponsors decide which approach is most optimal for a clinical trial.
-
.jpg?w=545&itok=L5olDoBO "EPR-Logo-Thumbnail-(1)")
The current and future landscape of HIV treatments and vaccines
Dr. Caroline Forkin discusses the current status of HIV treatments and potential for researchers to develop a vaccine.
-
Overcoming IVDR challenges for companion diagnostics
Angela Brown, Global Head and Senior Director, Regulatory Affairs and Nicole Cowan, Director, Project Management, IVD Operations & Strategy, provide expert commentary on overcoming IVDR challenges for companion diagnostics.
-
Best practices in managing CGT from protocol design to data management
Though the fields of immunotherapy and cell and gene therapies have seen significant growth since April 2012, CGT clinical research remains a challenge. ICON's Tamie Joeckel offers expert commentary on managing and executing CGT clinical trials.
.jpg?w=340&itok=lf7lPmaf "EPR-Logo-Thumbnail-(1)"){kind=icon}
